sc262
Generic: HIP-modified allogeneic CD22-directed CAR T cell
sc262: sourced relationships with 1 company · 1 clinical trial tracked.
sc262 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect sc262 to SANA; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could sc262 → SANA affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Non Hodgkin's LymphomaLarge B-cell Lymphoma
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Sana Biotechnology, Inc. (SANA) Non Hodgkin's Lymphoma | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1 Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin's Lymphoma (VIVID)
Primary endpoint: Evaluate safety and tolerability of SC262
Interventionalopen6 targetStarted 2024-04Completion 2029-033 sites · United StatesSana Biotechnology
Frequently asked questions
Which companies have sourced relationships with sc262?
sc262 has dated SEC/FDA relationship records for Sana Biotechnology, Inc..
How many clinical trials involve sc262?
BioSniper tracks 1 clinical trial involving sc262.